Subjects Fasting condition Insulin dose used to induce antecedent hypoglycaemia Insulin dose used to induce subsequent hypoglycaemia Depth and duration of antecedent hypoglycaemia Method of glucose assay Number of antecedent episodes Plasma adrenaline in response to antecedent/subsequent hypoglycaemia (in pg/mL) and method of assay Symptom scores during subsequent hypoglycaemia relative to that of antecedent hypoglycaemia Type 1 diabetes patients [14 –17 ] Overnight fasted prior to all days of experiments [16 , 17 ]14 , 15 ] 1-2 mU/kg/min [14 –17 ] 1-2 mU/kg/min [14 –17 ] 2.2–3.3 mmol/L [14 –17 ]14 , 16 , 17 ] Glucose dehydrogenase method [15 ] 14 , 16 , 17 ] 1/day for 1 day [14 , 16 ]17 ]15 ] 380/200; 14 ]17 ]15 ]16 ]15 ]14 , 16 , 17 ] Reduced neurogenic symptoms and neuroglycopenic symptoms 14 , 15 ] 17 ]16 ] Type 2 diabetes patients [18 ] Overnight fasted prior to all days of experiments [18 ] 1-2 mU/kg/min [18 ] 1-2 mU/kg/min [18 ] 2.2–3.3 mmol/L [18 ]18 ] Glucose oxidase method [18 ] 2/day for 1 day [18 ] No significant change in insulin treated patients18 ] 18 ] Reduced neurogenic symptoms and neuroglycopenic symptoms 18 ] Nondiabetic subjects [19 –27 ] Nonfasted [24 ] 19 –25 , 27 ] 1-2 mU/kg/min [19 –27 ] 1-2 mU/kg/min [19 –27 ] 2.2–2.8 mmol/L [21 –24 ]19 , 20 , 23 , 25 , 27 ]20 , 21 , 23 –26 ]22 ] Glucose oxidase method [20 –23 , 25 , 27 ]24 , 26 ] 1/day for 1 day [19 ]21 ]22 –27 ]20 ] 300–500/150–250;20 –22 , 25 ]19 , 23 , 26 , 27 ]24 ]21 , 22 , 24 , 26 , 27 ]20 , 23 ] Not measured [23 , 25 , 27 ]22 ] 24 ] 19 –21 ]
